The pathology lab triggers a trial referral the day a rare cancer is diagnosed
The pathologist is the first person to know a cancer is rare or has a targetable marker. A rule in the lab system could notify a trial team at that moment, before treatment decisions close the window.
Laboratory information systems flag defined diagnoses (rare histologies, MSI-high, NTRK fusion, specific paediatric-type tumours in adults) and send a structured notification to a regional trial coordination office and the treating clinician, with matched trials attached. Consent-to-contact rules govern direct patient contact. Precedents exist in stroke and sepsis alerting; oncology pathology alerting has been used for HER2 and MSI testing completeness.
- Trials enrol too few, too slowly · Fewer than one in ten adults with cancer joins a trial. Trials close for lack of patients, not lack of ideas.
- Rare and paediatric cancers without markets · Taken together rare cancers are a fifth of all cancers, but each one alone is too small for a company to invest in.
Pages like this
not linked directly; found by shared links- IdeaTrial-in-a-box: a preconfigured protocol kit any hospital can open for a rare cancer
Shares Trials enrol too few, too slowly, Neuroendocrine tumours, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- IdeaMandatory national virtual tumour boards for rare and complex cancers
Shares Neuroendocrine tumours, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- IdeaA funded expert second opinion for every new high-stakes or rare cancer diagnosis
Shares Neuroendocrine tumours, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- IdeaA same-week expert second opinion for every rare cancer diagnosis
Shares Histopathology & immunohistochemistry, Digital pathology & AI, Neuroendocrine tumours, Rare and paediatric cancers without markets.
- IdeaDegraders for the fusion proteins that drive childhood sarcomas
Shares Gene fusion, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- IdeaA standard for tumour-agnostic approvals: minimum histologies and hierarchical modelling
Shares Gene fusion, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Rare and paediatric cancers without markets.
- IdeaOne standing umbrella trial for all rare cancers in a country
Shares Trials enrol too few, too slowly, Neuroendocrine tumours, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- IdeaOne global rare cancer network with n-of-1 and Bayesian trial frameworks
Shares Neuroendocrine tumours, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).